Literature DB >> 23018872

Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders.

Samar M Said1, Carol Reynolds, Rafael E Jimenez, Beiyun Chen, Julie A Vrana, Jason D Theis, Ahmet Dogan, Sejal S Shah.   

Abstract

Amyloidosis is a disorder characterized by extracellular deposition of proteins in an abnormal fibrillar configuration. Amyloidosis can be localized or systemic and may affect any organ. Breast involvement by amyloidosis has rarely been reported. In this study, we described the characteristics of 40 cases of breast amyloidosis that were reviewed at the Division of Anatomic Pathology at Mayo Clinic from 1995 to 2011. The cohort included 39 women and 1 man with a mean age of 60 years. The type of amyloidosis, determined by immunohistochemistry or mass spectrometry-based proteomics in 26 patients, was immunoglobulin-associated in all cases (AL-kappa type in 15 (58%) cases, AL-lambda in 10 (38%) and mixed heavy and light chains (AH/AL) in 1 (4%) case). Mass spectrometry-based proteomics was able to determine the type of amyloidosis in 95% of cases tested compared with 69% of cases by immunohistochemistry. In addition to amyloidosis, the breast biopsy showed a hematologic disorder in 55% of cases, most commonly MALT lymphoma. One patient had concurrent intraductal carcinoma, but none had invasive carcinoma. Of the 15 patients seen in our institution, 53% had localized amyloidosis and 47% had extramammary amyloid involvement, which was diagnosed before breast amyloidosis in most patients. M-spike was detected in the blood in 62%. After a median follow-up of 33.5 months in 12 patients, 5 died, mostly of complications of lymphoma or leukemia. In conclusion, our findings indicate that breast amyloidosis is of the AL type in the vast majority of patients (usually kappa). It is associated with systemic amyloidosis in close to half of patients and with hematologic malignancy in the breast in over half of patients. Therefore, further work up to rule out hematologic malignancy and/or systemic amyloidosis is recommended. Mass spectrometry-based proteomics is superior to immunohistochemistry for typing of breast amyloidosis.

Entities:  

Mesh:

Year:  2012        PMID: 23018872     DOI: 10.1038/modpathol.2012.167

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  13 in total

1.  Adnexal mass secondary to extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with associated amyloid deposition.

Authors:  Neha Mehta; Heiko Schöder; April Chiu; John Kenneth Schoolmeester; Carol Portlock
Journal:  BMJ Case Rep       Date:  2014-11-14

2.  Breast MALT lymphoma and AL amyloidosis complicating Sjögren's syndrome.

Authors:  Nabil Belfeki; Salima Bellefquih; Anne Bourgarit
Journal:  BMJ Case Rep       Date:  2019-04-11

3.  Optimal conditions and the advantages of using laser microdissection and liquid chromatography tandem mass spectrometry for diagnosing renal amyloidosis.

Authors:  Michiko Aoki; Dedong Kang; Akira Katayama; Naomi Kuwahara; Shinya Nagasaka; Yoko Endo; Mika Terasaki; Shinobu Kunugi; Yasuhiro Terasaki; Akira Shimizu
Journal:  Clin Exp Nephrol       Date:  2018-01-25       Impact factor: 2.801

4.  Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.

Authors:  Julie A Vrana; Jason D Theis; Surendra Dasari; Oana M Mereuta; Angela Dispenzieri; Steven R Zeldenrust; Morie A Gertz; Paul J Kurtin; Karen L Grogg; Ahmet Dogan
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

5.  Primary amyloidosis of the breast presenting as a solitary nodule: case report and review of the literature.

Authors:  Mary E Huerter; Rasheed Hammadeh; Quan Zhou; Asher Weisberg; Adam I Riker
Journal:  Ochsner J       Date:  2014

6.  Primary MALT Lymphoma of the Breast Treated with Definitive Radiation.

Authors:  Mohammad Hissourou Iii; Sayyad Yaseen Zia; Mahfood Alqatari; James Strauchen; Richard L Bakst
Journal:  Case Rep Hematol       Date:  2016-05-10

7.  Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions.

Authors:  Tomomichi Kasagi; Hironobu Nobata; Keisuke Suzuki; Naoto Miura; Shogo Banno; Akiyoshi Takami; Taro Yamashita; Yukio Ando; Hirokazu Imai
Journal:  Intern Med       Date:  2017-01-01       Impact factor: 1.271

Review 8.  Localized primary amyloidosis of the breast: a case report and review of the literature.

Authors:  Wakako Tsuji; Eiji Takeuchi; Satoshi Oka; Taro Yamashita; Fumiaki Yotsumoto
Journal:  BMC Surg       Date:  2016-09-13       Impact factor: 2.102

9.  MALDI Mass Spectrometry Imaging: A Novel Tool for the Identification and Classification of Amyloidosis.

Authors:  Martin Winter; Andreas Tholey; Arnt Kristen; Christoph Röcken
Journal:  Proteomics       Date:  2017-11       Impact factor: 3.984

10.  Systemic amyloidoses and proteomics: The state of the art.

Authors:  Francesca Lavatelli; Andrea di Fonzo; Giovanni Palladini; Giampaolo Merlini
Journal:  EuPA Open Proteom       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.